Maternal High Blood Pressure and Newborn's Blood Profile

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

6108 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-01-01

Study Completion Date

2017-08-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Maternal high blood pressure remodels the intrauterine environment of the fetus by altering hormonal and cellular signaling patterns and, as a result increases the risk of fetal and neonatal mortality and morbidity. Newborns of these mothers have an increased risk of intrauterine growth restriction, premature birth and hematological abnormalities, such as thrombocytopenia, polycythemia, and neutropenia. The purpose of the article is to review neonatal thrombocytopenia and neutropenia as a consequence of maternal high blood pressure and to establish the optimal management of these cases.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cardiovascular Risk in Infants Exposed to Pre-eclampsia in Utero

NCT05091827

Offspring of Pre-eclamptic Mothers

UNKNOWN

Neurobehavioural Outcomes in Late Preterm Neonates

NCT02443259

Pre-Eclampsia

COMPLETED

The Trajectory of Blood Pressure During Pregnancy in Assisted Reproductive Females

NCT06426732

Blood Pressure

RECRUITING

Effects of Nitrate-rich Beetroot Juice in Pregnant Women With High Blood Pressure

NCT05241327

Preeclampsia Hypertension Endothelial Dysfunction +4 more

UNKNOWN NA

Effects of Dietary Nitrate in Hypertensive Pregnant Women

NCT02520687

Hypertension Pregnancy

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Pregnancy induced hypertension (PIH) and preeclampsia (preE) are caused by gestation and have an onset after 20 weeks of pregnancy. Although the exact etiology of PIH and preE remains unknown, two interconnected mechanisms have been identified to play an important role in the pathogenesis: dysfunction of the placental trophoblast and endothelial dysfunction within the maternal systemic vasculature. The endothelium has been identified as the target tissue of the disease. Endothelial alterations ultimately manifest as placental hypoxia and hypoplasia. The neonatal thrombocytopenia and neutropenia after pregnancy-induced hypertension is a result of inhibition of fetal bone marrow production of the myeloid lineage due to intrauterine hypoxic environment. This study aims to investigate the hematological profile in term and preterm infants born to mothers with preeclampsia. The current retrospective observational study was conducted at the Clinic of Obstetrics, Gynecology and Neonatology of the Emergency County Hospital, Timisoara over a period of three years, from January 2014 to December 2016. All inborn patient files were analyzed as anonymised limited data sets from archived records of the Neonatology Department.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Maternal-Fetal Exchange

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AGA Neonates

AGA Control Group Appropriate for gestational age newborns of healthy mothers

AGA - Control group

Intervention Type OTHER

Data processing from Patient Medical Files

SGA Neonates

SGA - Control Group Small for gestational age newborns of healthy mothers

SGA - Control group

Intervention Type OTHER

Data processing from Patient Medical Files

AGA-PIH Neonates

AGA-PIH Study Group Appropriate for gestational age newborns of mothers with pregnancy induced hypertension

AGA-PIH Study group

Intervention Type OTHER

Monitoring PIH-related changes in the newborn

SGA-PIH Neonates

SGA-PIH Study Group Small for gestational age newborns of mothers with pregnancy induced hypertension

SGA-PIH Study group

Intervention Type OTHER

Monitoring PIH-related changes in the newborn

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AGA - Control group

Data processing from Patient Medical Files

Intervention Type OTHER

SGA - Control group

Data processing from Patient Medical Files

Intervention Type OTHER

AGA-PIH Study group

Monitoring PIH-related changes in the newborn

Intervention Type OTHER

SGA-PIH Study group

Monitoring PIH-related changes in the newborn

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age: 0-28 days
* Newborns of healthy mothers;
* Newborns of mothers with Pregnancy Induced Hypertension;
* Inborn Patients;
* Written Informed Consent signed by legal guardian.